<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25668207</article-id><article-id pub-id-type="pmc">4337898</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0118084</article-id><article-id pub-id-type="publisher-id">PONE-D-14-38563</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genetic Investigation of Bisphosphonate-Related Osteonecrosis of Jaw
(BRONJ) via Whole Exome Sequencing and Bioinformatics</article-title><alt-title alt-title-type="running-head">Investigation of BRONJ Biomarkers</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jee-Hwan</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ko</surname><given-names>Yong Jae</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Ji-young</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Yoonsoo</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hwang</surname><given-names>Jihye</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Sangjin</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sanguk</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jae-Hoon</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Dong-Hoo</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Prosthodontics, College of Dentistry, Yonsei University, Seoul,
Korea</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Department of IT Convergence and Engineering, Pohang University of Science
and Technology, Pohang, Korea</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Department of Life Sciences, Pohang University of Science and Technology,
Pohang, Korea</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Department of Prosthodontics, College of Dentistry, Yonsei University, Seoul,
Korea</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Bj&#x000f6;rklund</surname><given-names>Peyman</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Uppsala University, SWEDEN</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: DHH JHL. Performed the experiments: SK JH.
Analyzed the data: SH YJK. Contributed reagents/materials/analysis tools: JHK.
Wrote the paper: YO JYK.</p></fn><corresp id="cor001">* E-mail: <email>jaehoon115@yuhs.ac</email> (JHL); <email>donghoohan@yuhs.ac</email> (DHH)</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>e0118084</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>4</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Kim et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Kim et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0118084.pdf"/><abstract><p>Complications associated with the use of bisphosphonate (BP) have risen over the
years due to an increase in the prescription of BP. BP-related osteonecrosis of jaw
(BRONJ), one of the complications linked to the consumption of BP, greatly affects
patients with minor dental trauma, incurring a long healing period. While BRONJ
afflicts only a minority of patients prescribed with BP, BRONJ is a multigenic
disease affected both by environmental and genetic factors having a distinctive
phenotype. This study aims to discover genetic biomarkers associated with BRONJ via
whole exome sequencing (WES) followed by statistical analysis. Sixteen individuals
who had been prescribed with bisphosphonate medication and diagnosed as BRONJ were
chosen and each individual&#x02019;s saliva sample was collected for WES. 126
randomized subsamples from the GSK project representing 109 male and 17 female
Koreans were used as a control data set. Fisher&#x02019;s exact test was carried out
to assess the significance of genetic variants in BRONJ patients. Gene set enrichment
analysis (GSEA) (DAVID Bioinformatics Resource 6.7) was used to perform a cluster
analysis of variants found from Fisher&#x02018;s exact test. The results from this
study suggest that BRONJ-inducing factors are genetically associated and BRONJ occurs
due to the malfunctioning of post-translational modification in osteoclast leading to
the impairment of cell morphology and adhesion.</p></abstract><funding-group><funding-statement>This work was supported by intramural grants from Yonsei University
College of Dentistry (Project No. 6-2012-0207). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the
manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All whole exome sequencing raw data was submitted to the SRA database
(SRA, <ext-link ext-link-type="uri" xlink:href="http://trace.ncbi.nlm.nih.gov/Traces/sra/">http://trace.ncbi.nlm.nih.gov/Traces/sra/</ext-link>, accession number
SRP045344). The list of control variants were added as <xref rid="pone.0118084.s005" ref-type="supplementary-material">S5
Table</xref>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All whole exome sequencing raw data was submitted to the SRA database
(SRA, <ext-link ext-link-type="uri" xlink:href="http://trace.ncbi.nlm.nih.gov/Traces/sra/">http://trace.ncbi.nlm.nih.gov/Traces/sra/</ext-link>, accession number
SRP045344). The list of control variants were added as <xref rid="pone.0118084.s005" ref-type="supplementary-material">S5
Table</xref>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Bisphosphonates (BP) are a commonly prescribed medication to treat bone metastases,
multiple myeloma, osteoporosis, and other bony diseases [<xref rid="pone.0118084.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0118084.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0118084.ref003" ref-type="bibr">3</xref>]. It is prescribed
at 73 percent of physician visits for osteoporosis in the United States [<xref rid="pone.0118084.ref004" ref-type="bibr">4</xref>]. No significant side effects have
been reported but patients prescribed with BP over a long period tend to experience
complications during healing after minor trauma in dentistry such as tooth extraction,
periodontal surgical operation, and tooth operations.</p><p>In 2003, it was first reported that bisphosphonate-related osteonecrosis of jaw (BRONJ)
derives from the exposure and necrosis of alveolar bone, pain, infection, and abscess
formation [<xref rid="pone.0118084.ref005" ref-type="bibr">5</xref>]; several other
cases have since followed [<xref rid="pone.0118084.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0118084.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0118084.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0118084.ref009" ref-type="bibr">9</xref>]. Many groups have recently published recommendations or
guidelines on prevention, staging, and management strategies for BRONJ [<xref rid="pone.0118084.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0118084.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0118084.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0118084.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0118084.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0118084.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0118084.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0118084.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0118084.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0118084.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0118084.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0118084.ref021" ref-type="bibr">21</xref>]. Nevertheless,
much needs to be done concerning the incidence, pathogenesis, treatment, and prevention
of BRONJ.</p><p>Patients who have received or been exposed to bisphosphonate and have not had
craniofacial region radiation therapy can be diagnosed with BRONJ if they have exposed
jaw bone that has not healed within 8 weeks after identification by a health care
provider. The 8-wk duration is consistent with the time frame in which most trauma,
extractions, and oral surgical procedures would have resulted in soft tissue closure and
exposed bone would no longer be present [<xref rid="pone.0118084.ref022" ref-type="bibr">22</xref>].</p><p>The incidence of the disease seems to be relatively low in patients receiving oral
bisphosphonates for osteoporosis or Paget&#x02019;s disease and considerably higher in
patients with malignancy receiving high doses of intravenous bisphosphonates. The mean
incidence after intravenous application was 7% and the overall incidence of BRONJ after
oral bisphosphonate application was 0.12% [<xref rid="pone.0118084.ref023" ref-type="bibr">23</xref>]. In a clinical investigation of BRONJ in patients with
malignant tumors, the disease recurred at the same sites in 7 out of 20 patients (37%)
and at different sites in 3 patients (16%) [<xref rid="pone.0118084.ref024" ref-type="bibr">24</xref>]. Not all patients receiving BP treatment experience BRONJ,
a clinical study showing an estimated risk of between 0.8% and 12% [<xref rid="pone.0118084.ref025" ref-type="bibr">25</xref>]. These varying statistical
values imply that BRONJ is a multifactorial disease involving several factors in
combination.</p><p>BP is known to inhibit osteoclastic bone resorption via attraction to and localization
in areas of the bone undergoing inflammation or resorption. Recently, substantial
evidence has emerged supporting such actions of BPs. Nitrogen-containing BPs are
subsequently phagocytized and internalized by osteoclasts, wherein they inhibit the
mevalonate pathway during cholesterol synthesis [<xref rid="pone.0118084.ref026" ref-type="bibr">26</xref>]. Such obstruction causes impairment of small GTPases of
the Ras family, which are known to be involved in cytoskeletal activity of
bone-resorbing osteoclasts [<xref rid="pone.0118084.ref026" ref-type="bibr">26</xref>].
The internalized BPs triggers apoptosis of osteoclasts, inhibiting osteoclast-mediated
bone resorption [<xref rid="pone.0118084.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0118084.ref028" ref-type="bibr">28</xref>].</p><p>Several studies on BRONJ-linked environmental risk factors have examined issues such as
the use of intravenous vs. oral BPs [<xref rid="pone.0118084.ref029" ref-type="bibr">29</xref>], concomitant use of chemotherapy [<xref rid="pone.0118084.ref030" ref-type="bibr">30</xref>], treatment with glucocorticoid [<xref rid="pone.0118084.ref010" ref-type="bibr">10</xref>] or thalidomide [<xref rid="pone.0118084.ref031" ref-type="bibr">31</xref>], length of exposure to BP
treatment [<xref rid="pone.0118084.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0118084.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0118084.ref034" ref-type="bibr">34</xref>], the presence of comorbid conditions such as obesity
[<xref rid="pone.0118084.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0118084.ref036" ref-type="bibr">36</xref>], alcohol and/or tobacco abuse
and pre-existing dental or periodontal disease. Among these, dental trauma such as tooth
extraction is known to be the most common immediate precipitation risk factor [<xref rid="pone.0118084.ref037" ref-type="bibr">37</xref>].</p><p>Other predisposing factors for BRONJ are age, race, smoking, obesity, cancer diagnosis,
and poor oral health, though these only account for a small percentage of the entire
risk [<xref rid="pone.0118084.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0118084.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0118084.ref038" ref-type="bibr">38</xref>]. Since patients with BP medication undergo similar
biological effects due to the intake of BP and considering that only a small number of
BP users experience BRONJ, it can be hypothesized that genetic susceptibility is
conferred by multiple genes regulating the metabolism of BP or skeletal homeostasis with
small variations [<xref rid="pone.0118084.ref039" ref-type="bibr">39</xref>]. If so,
BRONJ, like many other complex trait diseases, may be caused by a combination of
environmental and genetic risk factors.</p><p>Previous genetic association studies found various genes such as vascular endothelia
growth factor (<italic>VEGF</italic>), collagen Type 1 A 1 (<italic>COLIAI</italic>),
cytochrome P450 subfamily 2 polypeptide 8 (<italic>CYP2C8</italic>), farnesyl
disphosphate synthase gene, Matrix metalloproteinase-9 (<italic>MMP9</italic>), and
peroxisome proliferator-activated receptor gamma (<italic>PPARG</italic>) [<xref rid="pone.0118084.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0118084.ref041" ref-type="bibr">41</xref>,<xref rid="pone.0118084.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0118084.ref043" ref-type="bibr">43</xref>,<xref rid="pone.0118084.ref044" ref-type="bibr">44</xref>,<xref rid="pone.0118084.ref045" ref-type="bibr">45</xref>,<xref rid="pone.0118084.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0118084.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0118084.ref048" ref-type="bibr">48</xref>,<xref rid="pone.0118084.ref049" ref-type="bibr">49</xref>] to be associated with risk of developing BRONJ. Until
2004, genetic research depended on advanced technologies and case control studies
primarily identified only a small number of variants related to BRONJ.</p><p>Case-specific approaches have attempted to accommodate small case numbers. The first
genome-wide association study (GWAS) reported the rs1934951 (<italic>CYP2C8)</italic>
single nucleotide polymorphism (SNP) was associated with BRONJ in multiple myeloma (MM)
[<xref rid="pone.0118084.ref050" ref-type="bibr">50</xref>]. However, two other
studies reported that this SNP showed no correlation with jaw osteonecrosis in patients
suffering from prostate cancer and neither research group could confirm a significant
association between polymorphisms in the <italic>CYP2C8</italic> gene and the risk of
developing osteonecrosis of the jaw in patients with MM receiving treatment with BP in
an independent series [<xref rid="pone.0118084.ref051" ref-type="bibr">51</xref>,<xref rid="pone.0118084.ref052" ref-type="bibr">52</xref>]. So far, no single gene has been
verified as a risk factor despite numerous GWAS studies. This is due to the limitation
of GWAS in representing SNPs when only five thousand to one million bases out of three
billion human base pairs are analyzed. Newly discovered genetic indicators revealed the
limits of GWAS and gave rise to many discussions regarding missing heritability in GWAS.
A relatively new method, next generation sequencing (NGS), accommodates these
limitations.</p><p>In previous studies, a SNP array is commonly used to identify variants within a certain
range. One of the limitations of SNP arrays is that the analysis is done using the
preexisting reference SNP. The goal of this study is to find novel variants and to
include them in our analysis of both rare and common variants relating to BRONJ.
Therefore, Whole exome sequencing (WES), NGS technology, is more appropriate for the
purpose of this study.</p><p>NGS technology shifted genetic research from investigating known candidate genes to
revealing gene mutations and discovering candidate genes by comparing case and control.
Because NGS targets the exome, mutations in non-synonymous variants, splice sites, and
coding indels can be identified, particularly by focusing on non-synonymous mutations in
which changes in amino acids affect protein function. However, WES alone may not provide
pragmatic results in a multi-genic disease like BRONJ due to the extensive raw data,
pointing out the need to integrate data management and computational screening.
Incorporation of Gene Set Enrichment Analysis (GSEA) and a protein functional network
study of WES data may define enriched functions related with genetic variants implicitly
related to BRONJ. GSEA provides a novel way to functionally analyze a large number of
variants in a high-throughput fashion by classifying them into gene groups based on
their annotation term co-occurrence. The objective of this study was to discover genetic
biomarkers associated with BRONJ via WES GSEA, as well as network analysis followed by
statistical analysis and comparison with known genes.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Material and Methods</title><sec id="sec003"><title>1. Ethics Statement</title><p>All research involving human subjects or human data was approved by the Institutional
Review Board of Yonsei University College of Dentistry (Yonsei IRB No.
2&#x02013;2014&#x02013;0018). All clinical investigation was performed in accordance
with the Declaration of Helsinki. Written informed consent was obtained from all
subjects prior to participation.</p></sec><sec id="sec004"><title>2. Patient Selection</title><p>Sixteen individuals between 55 and 90 with BRONJ were analyzed using massively
parallel sequencing in this study (1 male, 15 female). Sixteen individuals had tooth
extraction or implant surgery in the Implant Clinic of Yonsei University Dental
Hospital from 2008 to 2013. These patients had a history of bisphosphonate medication
with varying duration, presence of exposed bone in the maxillofacial region for more
than eight weeks, and no history of radiation therapy to the jaws.</p></sec><sec id="sec005"><title>3. Control Data Set</title><p>126 randomized subsamples from the GSK project (Koreans; 109 male and 17 female) were
used as the control data set. The subsamples from the reference population consisted
of healthy Koreans regardless of gender and age originally recruited for a thyroid
cancer study (GSK project) (<xref rid="pone.0118084.s001" ref-type="supplementary-material">S1 Table</xref>).</p></sec><sec id="sec006"><title>4. Sample Collection</title><p>The sixteen individuals participating in this study were asked to collect 2 mL of
saliva in the tube of an Oragene DNA Self-Collection kit (DNA GenoTek, Ottawa,
Ontraio, Cat. #OG-500). DNA-preserving solution was mixed with the saliva, which was
sent to DNA Link Inc. (Seoul, South Korea) where collection of genomic DNA,
extraction of DNA, and further analysis were completed.</p></sec><sec id="sec007"><title>5. Whole Exome Sequencing on HISEQ 2500 using SureSelect All Exon kit
50Mb</title><p>Whole Exome Sequencing was done following the protocol reported in a previous study
[<xref rid="pone.0118084.ref053" ref-type="bibr">53</xref>].</p></sec><sec id="sec008"><title>6. Whole Exome Sequencing and variant analysis</title><p>Sequence QC was done through FastqQC 0.10.1, and then mapped to human reference
genome sequence NCBI b37 using bwa v0.7.5a. BAM files were realigned with the Genome
Analysis Toolkit 2.8&#x02013;1 (GATK) IndelRealigner, and base quality scores were
recalibrated using the GATK base quality recalibration tool. Variants were called
with GATK&#x02019;s UnifiedGenotyper tool. In order to filter potential errors, GATK
Variant Quality Score Recalibration (VQSR) was conducted based on hapmap 3.3, NCBI
Variation Database (dbSNP138), 1000 genome, and an Omni 2.5M SNP chip array. Then,
the variants&#x02019; functional information was annotated using SnpEff v3.6h with the
GRCh37.75 reference set. Variants found were then processed to find impact variants,
i.e., moderate and high variants as well as variants with call rates over 90% (<xref rid="pone.0118084.s002" ref-type="supplementary-material">S2 Table</xref>). High
impact variants are those variants that have a disruptive impact in protein and are
likely to affect the function of the protein, whereas moderate impact variants are
those that may or may not affect the protein. Genomic Evolutionary Rate Profiling
(GERP) and Polymorphism Phenotyping v2 (polyPhen-2) scores were applied to the
variants that matched the criteria and those that showed significance were subject to
further statistical analysis. For samples showing no result, a GERP greater than 2,
or Polyphen-2 results with D were filtered during this analysis.</p></sec><sec id="sec009"><title>7. Statistical analysis</title><p>Fisher&#x02019;s exact test was carried out to assess the significance of the variants
in BRONJ patients. Allelic, dominant, and recessive models were tested and variants
with p-value &#x0003c; 0.05 were chosen for each model. In this study, a 0.05 cutoff
indicates a broad view of association between the phenotype and genotype in the data.
The results were examined for multiple testing problems. Bonferroni correction with a
stricter cutoff of 3.75E-6 for statistical significance found significant variants.
Initially 15 variant genes were obtained by using Bonferroni correction with a
stricter cut-off (p-value&#x0003c; 3.75E-6). However, the initial gene set obtained
was not sufficient for the function enrichment analysis. In this study, rather than
analyzing the direct effect of disease genes, the relationship between genetic
variants in a functional network were analyzed. Therefore, the initial gene set was
expanded for further functional network analysis with a less strict cut-off (p-value
&#x0003c;0.05). As a result, 201 variant genes were obtained for the analysis of
functional association of pathogenesis of BRONJ. The significant SNPs were not
emphasized with Bonferroni correction because the main focus of the analysis was to
find functional significance rather than statistical significance with testing. A
call rate of greater than 90% was used. Three different analysis models (dominant,
recessive, and allelic) were used to compare genotype frequencies. In a dominant
model, a group of homozygote of the major frequency allele (A) was compared with
homozygote of minor allele (B) plus heterozygote (AA vs. AB+BB). In contrast to the
dominant model, the recessive model compared a group of homozygote of major allele
and heterozygote with a group of homozygote of minor allele (AA+AB vs. BB). Finally,
the allelic model compared the number of major and minor alleles (A vs. B) in cases
and controls.</p></sec><sec id="sec010"><title>8. Gene set enrichment analysis</title><p>Gene set enrichment analysis (DAVID Bioinformatics Resource 6.7) was used to perform
a cluster analysis of variants found through Fisher&#x02019;s exact test. GSEA was
applied to investigate genetic variants in groups of genes sharing a common
biological function, domain, or pathway. With the GSEA results, cluster enrichment
analysis was performed to build a protein functional network. The following
categories in DAVID were used. In the &#x02018;&#x02018;Functional Categories&#x0201d;
section, &#x02018;&#x02018;COG ONTOLOGY&#x0201d; and &#x02018;&#x02018;UP SEQ
FEATURE;&#x0201d; in the &#x02018;&#x02018;Gene Ontology&#x0201d; section:
&#x02018;&#x02018;GOTERM BP FAT&#x0201d;, &#x02018;&#x02018;GOTERM CC FAT,&#x0201d; and
&#x02018;&#x02018;GOTERM MF FAT;&#x0201d; in the &#x02018;&#x02018;Protein Domains&#x0201d;
section, &#x02018;&#x02018;INTERPRO,&#x0201d; &#x0201c;PIR SUPERFAMILY,&#x0201d; and
&#x02018;&#x02018;SMART;&#x02019; and finally, in the &#x02018;&#x02018;Pathways&#x0201d;
section, &#x02018;&#x02018;KEGG PATHWAY&#x0201d; was used. If the cluster had more than
one annotation term in &#x0201c;Initial Group membership&#x0201d; of Classification
Stringency Options, &#x0201c;Final Group Membership&#x0201d; was adjusted to
&#x0201c;2&#x0201d; in order to set the cluster.</p></sec><sec id="sec011"><title>9. Construction of a protein functional network</title><p>A protein functional network was visualized using the top ten clusters of the highest
enrichment scores. If different terms shared two or more genes, a link was made. Link
thickness represents the number of genes shared among distinct terms and node size
shows the number of genes in each term. <xref rid="pone.0118084.g001" ref-type="fig">Fig. 1</xref> outlines the filtration and prioritization framework used for data
analysis.</p><fig id="pone.0118084.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118084.g001</object-id><label>Fig 1</label><caption><title>An outline of variant selection for data analysis.</title></caption><graphic xlink:href="pone.0118084.g001"/></fig></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><p>All individuals had a history of BP medication with varying duration. Information
regarding all 16 individuals is provided in <xref rid="pone.0118084.s003" ref-type="supplementary-material">S3 Table</xref>. An average of 67,035,644 reads and
6,771 megabases were obtained from the sixteen individual&#x02019;s WES results. An
average of 4,138,925,783.75 total bases was aligned with a mean coverage depth of 80.36.
All information regarding number of reads, sample coverage, and sequencing depth, as
well as data quality, is summarized in <xref rid="pone.0118084.s004" ref-type="supplementary-material">S4 Table</xref>.</p><p>A total of 142 samples (16 case samples and 126 Korean GSK samples) were used for the
initial variant call. The selection yielded 219,722 variants, which were then processed
to find impact variants (moderate and high variants as well as variants with a call rate
over 90%). 69,187 variants were found to match the criteria, 13,325 variants showing
significance based on GERP and polyPhen scores. Fisher&#x02019;s Exact test was used to
improve statistical power and 201 variants were found to have a p-values &#x0003c; 0.05
(<xref rid="pone.0118084.s005" ref-type="supplementary-material">S5 Table</xref>).
Variants chosen were selected for subsequent gene set enrichment analysis. All whole
exome sequencing raw data was submitted to the SRA database (SRA, <ext-link ext-link-type="uri" xlink:href="http://trace.ncbi.nlm.nih.gov/Traces/sra/">http://trace.ncbi.nlm.nih.gov/Traces/sra/</ext-link>, accession
number SRP045344). Variants with affected number = 0 were included in the data analysis
because the conserved sequences in patients data showed meaningful differences compared
to the control set. The genes with &#x0201c;affected number = 0&#x0201d; have conserved
sequences in our 16 patient dataset while in the 126 control dataset, the same genes
showed multiple variations in the sequences [<xref rid="pone.0118084.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0118084.ref055" ref-type="bibr">55</xref>].</p><p>DAVID (DAVID v6.7) was used to canvass BRONJ pathogenic genes for enriched
functional-related gene groups. GSEA detected multiple gene sets related to cell
adhesion, regulation of cell morphology, and post-translational modification. Protein
functional network analysis was then performed to see how genes from different domains
related with each other in a biological system and how interactions between genes might
affect pathogenesis of BRONJ. To better understand the function of genetic variants from
BRONJ patients, we searched for significantly enriched gene function clusters (<xref rid="pone.0118084.s006" ref-type="supplementary-material">S6 Table</xref>). Cluster
enrichment was performed for the whole list of genes with mutations and the top 10
enriched clusters were picked for protein functional network analysis based on p-value.
Multiple testing corrections like Benjamini method was routinely used to reduce false
positive functional terms, however, at the same time, its strict cutoff may have
disrupted the selection of significant clusters among multiple gene sets[<xref rid="pone.0118084.ref054" ref-type="bibr">54</xref>]. Therefore, although significant
pathways were not found from Benjamini correction, gene functions and pathways were
selected with p-value analysis (p-value &#x0003c; 0.05, cluster enrichment score &#x0003e;
1.3, refer to <xref rid="pone.0118084.t001" ref-type="table">Table 1</xref> legend). The
purpose of this study was to depict how genetic variants are related to each other in a
biological system and to find their associations among enriched functions that may
affect the pathogenesis of BRONJ as a group of genes.</p><table-wrap id="pone.0118084.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118084.t001</object-id><label>Table 1</label><caption><title>Top 10 clusters ranked by enrichment score and representative terms in each
cluster from GSEA results (based on DAVID).</title></caption><alternatives><graphic id="pone.0118084.t001g" xlink:href="pone.0118084.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Nebulin</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 2.84</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Nebulin 35 residue motif</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1.55</td><td align="left" rowspan="1" colspan="1">6.72E-04</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Nebulin</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1.55</td><td align="left" rowspan="1" colspan="1">6.72E-04</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">SMART</td><td align="left" rowspan="1" colspan="1">NEBU</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1.55</td><td align="left" rowspan="1" colspan="1">8.28E-04</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Basal plasma membrane</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 2.53</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">basolateral plasma membrane</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4.64</td><td align="left" rowspan="1" colspan="1">2.01E-03</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">basal plasma membrane</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">2.95E-03</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">basal part of cell</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">4.46E-03</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cytoskeleton</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.83</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">cytoskeleton</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">14.43</td><td align="left" rowspan="1" colspan="1">2.68E-03</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">cytoskeletal part</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">10.82</td><td align="left" rowspan="1" colspan="1">4.59E-03</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">microtubule cytoskeleton</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">6.70</td><td align="left" rowspan="1" colspan="1">2.02E-02</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>EGF</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.81</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">EGF-like region, conserved site</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">6.19</td><td align="left" rowspan="1" colspan="1">3.20E-04</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">EGF-like, type 3</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">4.12</td><td align="left" rowspan="1" colspan="1">4.89E-03</td><td align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">EGF calcium-binding</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2.58</td><td align="left" rowspan="1" colspan="1">7.37E-03</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ubl &#x00026; Isopeptide bond</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.81</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">SP_PIR_KEYWORDS</td><td align="left" rowspan="1" colspan="1">ubl conjugation</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">7.22</td><td align="left" rowspan="1" colspan="1">6.01E-03</td><td align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">SP_PIR_KEYWORDS</td><td align="left" rowspan="1" colspan="1">isopeptide bond</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">4.12</td><td align="left" rowspan="1" colspan="1">4.05E-02</td><td align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Immunoglobulin</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.74</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Fibronectin, type III-like fold</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4.64</td><td align="left" rowspan="1" colspan="1">8.23E-04</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Fibronectin, type III</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4.64</td><td align="left" rowspan="1" colspan="1">1.01E-03</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">SMART</td><td align="left" rowspan="1" colspan="1">FN3</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4.64</td><td align="left" rowspan="1" colspan="1">1.88E-03</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cell adhesion</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.70</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">proteinaceous extracellular matrix</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">5.67</td><td align="left" rowspan="1" colspan="1">3.19E-03</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">extracellular matrix</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">5.67</td><td align="left" rowspan="1" colspan="1">5.40E-03</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">SP_PIR_KEYWORDS</td><td align="left" rowspan="1" colspan="1">cell binding</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1.55</td><td align="left" rowspan="1" colspan="1">9.46E-03</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SH3</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.68</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">SP_PIR_KEYWORDS</td><td align="left" rowspan="1" colspan="1">sh3 domain</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">4.12</td><td align="left" rowspan="1" colspan="1">5.09E-03</td><td align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Src homology-3 domain</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3.61</td><td align="left" rowspan="1" colspan="1">2.70E-02</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Variant SH3</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">3.23E-02</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Protease</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.65</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">PIR_SUPERFAMILY</td><td align="left" rowspan="1" colspan="1">serpin</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">6.23E-03</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Protease inhibitor I4, serpin</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">8.87E-03</td><td align="left" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">SMART</td><td align="left" rowspan="1" colspan="1">SERPIN</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">1.18E-02</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Motor protein</bold>
</td><td colspan="5" align="left" rowspan="1">
<bold>Enrichment Score: 1.63</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Term</td><td align="left" rowspan="1" colspan="1">Count</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Benjamini</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Dynein heavy chain, N-terminal region 2</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">6.06E-04</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">INTERPRO</td><td align="left" rowspan="1" colspan="1">Dynein heavy chain</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">6.06E-04</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC_FAT</td><td align="left" rowspan="1" colspan="1">dynein complex</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.06</td><td align="left" rowspan="1" colspan="1">6.37E-03</td><td align="left" rowspan="1" colspan="1">0.17</td></tr></tbody></table></alternatives></table-wrap><p>We provide a list of all annotation terms in each cluster as <xref rid="pone.0118084.s004" ref-type="supplementary-material">S4 Table</xref>. Enrichment
score is the geometric mean of all the enrichment P-values for each annotations term
associated with the genes in genetic variant list from BRONJ patients. P-value of each
term in each cluster means the significance of the term enrichment with a modified
Fisher&#x02019;s exact test. Enrichment score of 1.3 is equivalent that average of
P-values of the terms in cluster is 0.05. Count and percentage (%) in the table show the
number of genes that are involved in the annotation term and the ratio of genes related
with the term to total genetic variants. Benjamini is one of the multiple testing
correction techniques.</p><p>Representative terms in each cluster were listed in <xref rid="pone.0118084.t001" ref-type="table">Table 1</xref>. Protein functional network analysis (<xref rid="pone.0118084.g002" ref-type="fig">Fig. 2</xref>) showed numerous mutations in
genes affecting cell morphology and cell adhesion and binding. Functional terms and the
number of shared genes between two terms in the protein functional network analysis were
described using circles, nodes, and lines. Nodes describe functional terms in each
cluster, lines express the number of genes shared by each term, node size indicates the
number of genetic variants, and link thickness signifies the number of shared genes.
Yellow circles represent enriched clusters of gene functions involved in the regulation
of cytoskeleton, cell adhesion, and regulation of post-translational modification. These
clusters are linked through genes related to post-translational modification such as
those affecting ubiquitin-like proteins (UBLs) and isopeptide bonds. UBLs are known to
influence substrate affinity, localization, and stability of other proteins by forming
isopeptide bonds [<xref rid="pone.0118084.ref055" ref-type="bibr">55</xref>].
Cytoskeletal proteins such as tubulin, actin, and myosin also form isopeptide bonds with
the extracellular matrix-associated proteins including collagen, fibronectin, and
laminin [<xref rid="pone.0118084.ref056" ref-type="bibr">56</xref>,<xref rid="pone.0118084.ref057" ref-type="bibr">57</xref>].</p><fig id="pone.0118084.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118084.g002</object-id><label>Fig 2</label><caption><title>Analysis of gene function enrichment and construction of functional
network.</title><p>Each cluster is represented as a yellow circle, in which nodes show all terms
included in the cluster. A representative term was selected to describe each
cluster. Node size shows the number of genes mapped in the network. Nodes were
color-coded according to their characteristics: genes related to cell morphology
(pink), cell adhesion and binding (green), Ubiquitin-like proteins and isopeptide
bond (red), and proteases (yellow). If different terms share two or more genes, a
link was given. Links express the number of genes shared among distinct terms.</p></caption><graphic xlink:href="pone.0118084.g002"/></fig></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>As it was indicated earlier, the aim of this study was to identify all the biomarkers
associated with BRONJ by comparing the genetic information of experimental group with
the control group. Generally, in other studies with Whole Exome Sequencing, multiple
methods were used to validate the result of variant calling in an effort to minimize the
error in the process. However, in this study the validation of variant calling was not
performed, because the main focus of this study was to identify new variants associated
with BRONJ rather than to identify the location of affected transcript in the mutation.
One of the limitations of this study was that although Whole Exome Sequencing is
effective in finding the variants responsible for BRONJ, it cannot find the structural
information about variants [<xref rid="pone.0118084.ref059" ref-type="bibr">59</xref>].
If one wants to find the affected transcript in variants as is in many researches on
cancer or tumor, transcriptome sequencing with different genome sample is necessary.
Because this study used saliva samples as a method of collecting DNA, transcriptome
sequencing could not be done because it requires tissue samples. The method of whole
exome sequencing was adequate for the purpose of this research, which was to detect all
the variants associated with BRONJ. However, in in order to study these variants in
depth, future study is warranted with transcriptome sequencing, which will allow
detection of affected transcript within these variants.</p><p>The subjects in the experimental and control groups differed considerably in gender
selection. The experimental group had more female participants whereas the control group
had more male subjects. Gender bias in the experimental group was accidental and
inevitable due to the nature of this study. Currently, bisphosphonates are widely
prescribed for patients with osteoporosis. Since osteoporosis is more prevalent in
female, bisphosphonate is used more among females. Due to higher use of bisphosphonates
in female, higher representation of female patients with bisphosphonate-associated BRONJ
was expected in experimental group. Because the incidence of BRONJ is low, the gender
difference in incidence remains unknown and needs further study. The effect of gender
bias in our experimental group in this study is not clear [<xref rid="pone.0118084.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0118084.ref058" ref-type="bibr">58</xref>,<xref rid="pone.0118084.ref059" ref-type="bibr">59</xref>].</p><p>Despite many hypotheses (including remodeling suppression, infection, and angiogenesis
disorder), the exact mechanism behind BRONJ is still unclear [<xref rid="pone.0118084.ref060" ref-type="bibr">60</xref>]. Remodeling suppression through
inhibition of the mevalonate pathway is the best-known hypothesis. Nitrogen-containing
BPs that inhibit the mevalonate pathway in osteoclast interfere with post-translational
modification by blocking membrane transport across the endoplasmic reticulum. BPs
absorbed by osteoclast act as an inhibitor of farnesyl pyrophosphate synthase, an
ubiquitin-like protein, preventing the biosynthesis of small GTPase signaling proteins
[<xref rid="pone.0118084.ref002" ref-type="bibr">2</xref>]. These GTP-binding
proteins (Ras, Pho, Rac, Rab) are important for cellular growth and are involved in
cytoskeletal activity of bone-resorbing osteoclasts [<xref rid="pone.0118084.ref061" ref-type="bibr">61</xref>,<xref rid="pone.0118084.ref062" ref-type="bibr">62</xref>].
Transport across the endoplasmic reticulum is interrupted in the process so that ruffled
borders no longer form along the osteoclast cell membrane [<xref rid="pone.0118084.ref026" ref-type="bibr">26</xref>]. As a result, sequestrum is
found where necrosis has occurred in the bone remodeling process. As mentioned earlier,
BRONJ may be due to combination of predisposing factors and multigentic factors. This
study attempted to find a multigenic module responsible for BRONJ [<xref rid="pone.0118084.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0118084.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0118084.ref038" ref-type="bibr">38</xref>].
Of the 201 significant variables found in this study, the highest 10 variants with the
lowest p-values were looked at for their effect on BRONJ. Genes ARSD, SLC25A5, CCNYL2,
PGYM were among the top 10 variants found. One functionally relevant gene was ARSD,
which codes for the protein which participates in bone composition. SLC25A5 is known to
code for the protein responsible for transferring energy in the cell and whose mutation
may lead to dysfunction in cell metabolism [<xref rid="pone.0118084.ref002" ref-type="bibr">2</xref>]. These genes did not have a direct phenotypical effect on
BRONJ but may participate in cell morphology and cell function. It has been reported
that transglutaminase regulates the bone remodeling process by forming isopeptide bonds
during protein post-translational modification. Transglutaminase is an Ubiqutin-like
protein which modulates GTPase activity. The enzyme behaves as a multifunctional protein
involved in inflammatory effects through GTP hydrolyzation and protein cross linking.
BPs interfere with transglutaminase regulation and inhibit osteoclast activity.</p><p>In this study, we found genetic mutations in variants which regulate post-translational
maturation. Significant differences between BRONJ patients and the control group
appeared in genes related to ubiquitin-like proteins, isopeptide bonds, cell adhesion,
and cytoskeleton. These genes are responsible for post-translational maturation and can
affect cell differentiation [<xref rid="pone.0118084.ref057" ref-type="bibr">57</xref>].
The results from this study suggest that BRONJ-inducing factors are genetically
associated and that BRONJ arises due to the malfunctioning of post-translational
modification in osteoclast, leading to the impairment of cell morphology and
adhesion.</p><p>Despite all statistics regarding BRONJ and BP prescriptions given to osteoporosis
patients, the effect of BP use needs to be ascertained by classifying all complications
that arise in medical procedures. Among the few BRONJ diagnostic methods are
serodiagnosis such as serum CTX (carboxy-terminal collagen crosslinks) and measuring the
level of osteocalcin to diagnose the risk of developing BRONJ. Radiologic examination
such as bone scintigraphy and MRI are often used in current clinical practice despite
their inaccuracy because there is no better diagnostic tool for measuring the risk of
developing BRONJ at this point [<xref rid="pone.0118084.ref063" ref-type="bibr">63</xref>,<xref rid="pone.0118084.ref064" ref-type="bibr">64</xref>]. It is thus
essential to develop an innovative diagnostic tool for BRONJ.</p></sec><sec sec-type="conclusions" id="sec014"><title>Conclusion</title><p>BP in the biological system is known to inhibit osteoclastic bone resorption via
phagocytosis and internalization by osteoclasts, triggering apoptosis of osteoclasts and
eventually inhibiting osteoclast-mediated bone resorption. BPs inhibit the
post-translational modification process by blocking the mevalonate pathway in osteoclast
and preventing ruffled borders from forming along the osteoclast cell membrane. In this
study a significant difference between BRONJ patients and randomized subsamples group
was found in genes related to ubiquitin-like proteins, isopeptide bonds, cell adhesion,
and cytoskeleton, all of which are involved in post-translational maturation. One may
conclude that BRONJ-inducing factors are genetically associated and cause the
malfunctioning of post-translational modification in osteoclast leading to the
impairment of cell morphology and adhesion. Genetic diagnosis of BRONJ can help
clinicians determine appropriate treatment and thus reduce possible complications. Also,
post-translational maturation in the mevalonate pathway can be further investigated
through genetic research similar to the current study to elucidate the mechanism of
BRONJ pathogenesis in detail. Further research with more cases and controls, along with
functional animal studies, may produce legitimate biomarkers for early diagnosis of
BRONJ.</p></sec><sec sec-type="supplementary-material" id="sec015"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0118084.s001"><label>S1 Table</label><caption><title>List of control variants.</title><p>(XLSX)</p></caption><media xlink:href="pone.0118084.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0118084.s002"><label>S2 Table</label><caption><title>List of case variants.</title><p>(XLSX)</p></caption><media xlink:href="pone.0118084.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0118084.s003"><label>S3 Table</label><caption><title>Patient information.</title><p>(DOCX)</p></caption><media xlink:href="pone.0118084.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0118084.s004"><label>S4 Table</label><caption><title>Summary of the number of reads and coverage.</title><p>(DOCX)</p></caption><media xlink:href="pone.0118084.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0118084.s005"><label>S5 Table</label><caption><title>Full list of genes.</title><p>(DOCX)</p></caption><media xlink:href="pone.0118084.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0118084.s006"><label>S6 Table</label><caption><title>List of the annotations in each cluster.</title><p>(XLSX)</p></caption><media xlink:href="pone.0118084.s006.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0118084.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Carter</surname><given-names>G</given-names></name>, <name><surname>Goss</surname><given-names>AN</given-names></name>, <name><surname>Doecke</surname><given-names>C</given-names></name> (<year>2005</year>) <article-title>Bisphosphonates and avascular necrosis of
the jaw: a possible association</article-title>. <source>Med J Aust</source>
<volume>182</volume>: <fpage>413</fpage>&#x02013;<lpage>415</lpage>.
<pub-id pub-id-type="pmid">15850439</pub-id></mixed-citation></ref><ref id="pone.0118084.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Drake</surname><given-names>MT</given-names></name>, <name><surname>Clarke</surname><given-names>BL</given-names></name>, <name><surname>Khosla</surname><given-names>S</given-names></name> (<year>2008</year>) <article-title>Bisphosphonates: mechanism of action and
role in clinical practice</article-title>. <source>Mayo Clin Proc</source>
<volume>83</volume>: <fpage>1032</fpage>&#x02013;<lpage>1045</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4065/83.9.1032">10.4065/83.9.1032</ext-link></comment>
<pub-id pub-id-type="pmid">18775204</pub-id></mixed-citation></ref><ref id="pone.0118084.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Greenberg</surname><given-names>MS</given-names></name> (<year>2004</year>) <article-title>Intravenous bisphosphonates and
osteonecrosis</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol
Endod</source>
<volume>98</volume>: <fpage>259</fpage>&#x02013;<lpage>260</lpage>.
<pub-id pub-id-type="pmid">15356460</pub-id></mixed-citation></ref><ref id="pone.0118084.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Stafford</surname><given-names>RS</given-names></name>, <name><surname>Drieling</surname><given-names>RL</given-names></name>, <name><surname>Hersh</surname><given-names>AL</given-names></name> (<year>2004</year>) <article-title>National trends in osteoporosis visits and
osteoporosis treatment, 1988&#x02013;2003</article-title>. <source>Arch Intern
Med</source>
<volume>164</volume>: <fpage>1525</fpage>&#x02013;<lpage>1530</lpage>.
<pub-id pub-id-type="pmid">15277283</pub-id></mixed-citation></ref><ref id="pone.0118084.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Goodger</surname><given-names>NM</given-names></name>, <name><surname>Pogrel</surname><given-names>MA</given-names></name> (<year>2003</year>) <article-title>Osteonecrosis of the jaws associated with
cancer chemotherapy</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>61</volume>: <fpage>1104</fpage>&#x02013;<lpage>1107</lpage>.
<pub-id pub-id-type="pmid">12966490</pub-id></mixed-citation></ref><ref id="pone.0118084.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Capsoni</surname><given-names>F</given-names></name>, <name><surname>Longhi</surname><given-names>M</given-names></name>, <name><surname>Weinstein</surname><given-names>R</given-names></name> (<year>2006</year>) <article-title>Bisphosphonate-associated osteonecrosis of
the jaw: the rheumatologist&#x02019;s role</article-title>. <source>Arthritis Res
Ther</source>
<volume>8</volume>: <fpage>219</fpage>
<pub-id pub-id-type="pmid">17049069</pub-id></mixed-citation></ref><ref id="pone.0118084.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Conte</surname><given-names>P</given-names></name>, <name><surname>Guarneri</surname><given-names>V</given-names></name> (<year>2004</year>) <article-title>Safety of intravenous and oral
bisphosphonates and compliance with dosing regimens</article-title>.
<source>Oncologist</source>
<volume>9</volume>
<issue>Suppl 4</issue>: <fpage>28</fpage>&#x02013;<lpage>37</lpage>.
<pub-id pub-id-type="pmid">15459427</pub-id></mixed-citation></ref><ref id="pone.0118084.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Markiewicz</surname><given-names>MR</given-names></name>, <name><surname>Margarone</surname><given-names>JE</given-names><suffix>3rd</suffix></name>, <name><surname>Campbell</surname><given-names>JH</given-names></name>, <name><surname>Aguirre</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>Bisphosphonate-associated osteonecrosis of
the jaws: a review of current knowledge</article-title>. <source>J Am Dent
Assoc</source>
<volume>136</volume>: <fpage>1669</fpage>&#x02013;<lpage>1674</lpage>.
<pub-id pub-id-type="pmid">16383048</pub-id></mixed-citation></ref><ref id="pone.0118084.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Ruggiero</surname><given-names>SL</given-names></name>, <name><surname>Drew</surname><given-names>SJ</given-names></name> (<year>2007</year>) <article-title>Osteonecrosis of the jaws and
bisphosphonate therapy</article-title>. <source>J Dent Res</source>
<volume>86</volume>: <fpage>1013</fpage>&#x02013;<lpage>1021</lpage>.
<pub-id pub-id-type="pmid">17959890</pub-id></mixed-citation></ref><ref id="pone.0118084.ref010"><label>10</label><mixed-citation publication-type="journal">
<collab>Advisory Task
Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoO</collab>, <name><surname>Maxillofacial</surname><given-names>S</given-names></name> (<year>2007</year>) <article-title>American Association of Oral and
Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of
the jaws</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>65</volume>: <fpage>369</fpage>&#x02013;<lpage>376</lpage>.
<pub-id pub-id-type="pmid">17307580</pub-id></mixed-citation></ref><ref id="pone.0118084.ref011"><label>11</label><mixed-citation publication-type="journal">
<collab>American Dental
Association Council on Scientific A</collab> (<year>2006</year>)
<article-title>Dental management of patients receiving oral bisphosphonate
therapy: expert panel recommendations</article-title>. <source>J Am Dent
Assoc</source>
<volume>137</volume>: <fpage>1144</fpage>&#x02013;<lpage>1150</lpage>.
<pub-id pub-id-type="pmid">16873332</pub-id></mixed-citation></ref><ref id="pone.0118084.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Bagan</surname><given-names>J</given-names></name>, <name><surname>Blade</surname><given-names>J</given-names></name>, <name><surname>Cozar</surname><given-names>JM</given-names></name>, <name><surname>Constela</surname><given-names>M</given-names></name>, <name><surname>Garcia Sanz</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Recommendations for
the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in
cancer patients treated with bisphosphonates</article-title>. <source>Med Oral
Patol Oral Cir Bucal</source>
<volume>12</volume>: <fpage>E336</fpage>&#x02013;<lpage>340</lpage>.
<pub-id pub-id-type="pmid">17664922</pub-id></mixed-citation></ref><ref id="pone.0118084.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Edwards</surname><given-names>BJ</given-names></name>, <name><surname>Hellstein</surname><given-names>JW</given-names></name>, <name><surname>Jacobsen</surname><given-names>PL</given-names></name>, <name><surname>Kaltman</surname><given-names>S</given-names></name>, <name><surname>Mariotti</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Updated
recommendations for managing the care of patients receiving oral bisphosphonate
therapy: an advisory statement from the American Dental Association Council on
Scientific Affairs</article-title>. <source>J Am Dent Assoc</source>
<volume>139</volume>: <fpage>1674</fpage>&#x02013;<lpage>1677</lpage>.
<pub-id pub-id-type="pmid">19047674</pub-id></mixed-citation></ref><ref id="pone.0118084.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Khan</surname><given-names>AA</given-names></name>, <name><surname>Sandor</surname><given-names>GK</given-names></name>, <name><surname>Dore</surname><given-names>E</given-names></name>, <name><surname>Morrison</surname><given-names>AD</given-names></name>, <name><surname>Alsahli</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Canadian consensus
practice guidelines for bisphosphonate associated osteonecrosis of the
jaw</article-title>. <source>J Rheumatol</source>
<volume>35</volume>: <fpage>1391</fpage>&#x02013;<lpage>1397</lpage>.
<pub-id pub-id-type="pmid">18528958</pub-id></mixed-citation></ref><ref id="pone.0118084.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Khosla</surname><given-names>S</given-names></name>, <name><surname>Burr</surname><given-names>D</given-names></name>, <name><surname>Cauley</surname><given-names>J</given-names></name>, <name><surname>Dempster</surname><given-names>DW</given-names></name>, <name><surname>Ebeling</surname><given-names>PR</given-names></name>, <etal>et al</etal> (<year>2007</year>)
<article-title>Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a
Task Force of the American Society for Bone and Mineral Research</article-title>.
<source>Journal of Bone and Mineral Research</source>
<volume>22</volume>: <fpage>1479</fpage>&#x02013;<lpage>1491</lpage>.
<pub-id pub-id-type="pmid">17663640</pub-id></mixed-citation></ref><ref id="pone.0118084.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>McLeod</surname><given-names>NM</given-names></name>, <name><surname>Patel</surname><given-names>V</given-names></name>, <name><surname>Kusanale</surname><given-names>A</given-names></name>, <name><surname>Rogers</surname><given-names>SN</given-names></name>, <name><surname>Brennan</surname><given-names>PA</given-names></name> (<year>2011</year>) <article-title>Bisphosphonate osteonecrosis of the jaw: a
literature review of UK policies versus international policies on the management
of bisphosphonate osteonecrosis of the jaw</article-title>. <source>Br J Oral
Maxillofac Surg</source>
<volume>49</volume>: <fpage>335</fpage>&#x02013;<lpage>342</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bjoms.2010.08.005">10.1016/j.bjoms.2010.08.005</ext-link></comment>
<pub-id pub-id-type="pmid">20863603</pub-id></mixed-citation></ref><ref id="pone.0118084.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Migliorati</surname><given-names>CA</given-names></name>, <name><surname>Casiglia</surname><given-names>J</given-names></name>, <name><surname>Epstein</surname><given-names>J</given-names></name>, <name><surname>Jacobsen</surname><given-names>PL</given-names></name>, <name><surname>Siegel</surname><given-names>MA</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Managing the care of
patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral
Medicine position paper</article-title>. <source>The Journal of the American
Dental Association</source>
<volume>136</volume>: <fpage>1658</fpage>&#x02013;<lpage>1668</lpage>.
<pub-id pub-id-type="pmid">16383047</pub-id></mixed-citation></ref><ref id="pone.0118084.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Ruggiero</surname><given-names>S</given-names></name>, <name><surname>Gralow</surname><given-names>J</given-names></name>, <name><surname>Marx</surname><given-names>RE</given-names></name>, <name><surname>Hoff</surname><given-names>AO</given-names></name>, <name><surname>Schubert</surname><given-names>MM</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Practical Guidelines
for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in
Patients With Cancer</article-title>. <source>Journal of Oncology
Practice</source>
<volume>2</volume>: <fpage>7</fpage>&#x02013;<lpage>14</lpage>.
<pub-id pub-id-type="pmid">20871729</pub-id></mixed-citation></ref><ref id="pone.0118084.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Ruggiero</surname><given-names>SL</given-names></name>, <name><surname>Dodson</surname><given-names>TB</given-names></name>, <name><surname>Assael</surname><given-names>LA</given-names></name>, <name><surname>Landesberg</surname><given-names>R</given-names></name>, <name><surname>Marx</surname><given-names>RE</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>American Association
of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related
osteonecrosis of the jaws&#x02014;2009 update</article-title>. <source>J Oral
Maxillofac Surg</source>
<volume>67</volume>: <fpage>2</fpage>&#x02013;<lpage>12</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2009.06.016">10.1016/j.joms.2009.06.016</ext-link></comment>
<pub-id pub-id-type="pmid">19835745</pub-id></mixed-citation></ref><ref id="pone.0118084.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Tubiana-Hulin</surname><given-names>M</given-names></name>, <name><surname>Spielmann</surname><given-names>M</given-names></name>, <name><surname>Roux</surname><given-names>C</given-names></name>, <name><surname>Campone</surname><given-names>M</given-names></name>, <name><surname>Zelek</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Physiopathology and
management of osteonecrosis of the jaws related to bisphosphonate therapy for
malignant bone lesions. A French expert panel analysis</article-title>.
<source>Crit Rev Oncol Hematol</source>
<volume>71</volume>: <fpage>12</fpage>&#x02013;<lpage>21</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.critrevonc.2008.10.009">10.1016/j.critrevonc.2008.10.009</ext-link></comment>
<pub-id pub-id-type="pmid">19070505</pub-id></mixed-citation></ref><ref id="pone.0118084.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Weitzman</surname><given-names>R</given-names></name>, <name><surname>Sauter</surname><given-names>N</given-names></name>, <name><surname>Eriksen</surname><given-names>EF</given-names></name>, <name><surname>Tarassoff</surname><given-names>PG</given-names></name>, <name><surname>Lacerna</surname><given-names>LV</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Critical review:
updated recommendations for the prevention, diagnosis, and treatment of
osteonecrosis of the jaw in cancer patients&#x02014;May 2006</article-title>.
<source>Crit Rev Oncol Hematol</source>
<volume>62</volume>: <fpage>148</fpage>&#x02013;<lpage>152</lpage>.
<pub-id pub-id-type="pmid">17336086</pub-id></mixed-citation></ref><ref id="pone.0118084.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Khosla</surname><given-names>S</given-names></name>, <name><surname>Burr</surname><given-names>D</given-names></name>, <name><surname>Cauley</surname><given-names>J</given-names></name>, <name><surname>Dempster</surname><given-names>DW</given-names></name>, <name><surname>Ebeling</surname><given-names>PR</given-names></name>, <etal>et al</etal> (<year>2007</year>)
<article-title>Bisphosphonate-associated osteonecrosis of the jaw: report of a
task force of the American Society for Bone and Mineral Research</article-title>.
<source>J Bone Miner Res</source>
<volume>22</volume>: <fpage>1479</fpage>&#x02013;<lpage>1491</lpage>.
<pub-id pub-id-type="pmid">17663640</pub-id></mixed-citation></ref><ref id="pone.0118084.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Kuhl</surname><given-names>S</given-names></name>, <name><surname>Walter</surname><given-names>C</given-names></name>, <name><surname>Acham</surname><given-names>S</given-names></name>, <name><surname>Pfeffer</surname><given-names>R</given-names></name>, <name><surname>Lambrecht</surname><given-names>JT</given-names></name> (<year>2012</year>) <article-title>Bisphosphonate-related osteonecrosis of
the jaws&#x02014;a review</article-title>. <source>Oral Oncol</source>
<volume>48</volume>: <fpage>938</fpage>&#x02013;<lpage>947</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.oraloncology.2012.03.028">10.1016/j.oraloncology.2012.03.028</ext-link></comment>
<pub-id pub-id-type="pmid">22525606</pub-id></mixed-citation></ref><ref id="pone.0118084.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Kim</surname><given-names>S-KK</given-names></name>, <name><surname>Tea-Geon</surname></name> (<year>2012</year>) <article-title>Clinical investigation of
bisphosphonate-related osteonecrosis of the jaws in patients with malignant
tumors</article-title>. <source>Journal of the Korean association of oral and
maxillofacial surgeons</source>
<volume>38</volume>: <fpage>152</fpage>&#x02013;<lpage>159</lpage>.</mixed-citation></ref><ref id="pone.0118084.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Saia</surname><given-names>G</given-names></name>, <name><surname>Blandamura</surname><given-names>S</given-names></name>, <name><surname>Bettini</surname><given-names>G</given-names></name>, <name><surname>Tronchet</surname><given-names>A</given-names></name>, <name><surname>Totola</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Occurrence of
bisphosphonate-related osteonecrosis of the jaw after surgical tooth
extraction</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>68</volume>: <fpage>797</fpage>&#x02013;<lpage>804</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2009.10.026">10.1016/j.joms.2009.10.026</ext-link></comment>
<pub-id pub-id-type="pmid">20307765</pub-id></mixed-citation></ref><ref id="pone.0118084.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Alakangas</surname><given-names>A</given-names></name>, <name><surname>Selander</surname><given-names>K</given-names></name>, <name><surname>Mulari</surname><given-names>M</given-names></name>, <name><surname>Halleen</surname><given-names>J</given-names></name>, <name><surname>Lehenkari</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Alendronate disturbs
vesicular trafficking in osteoclasts</article-title>. <source>Calcif Tissue
Int</source>
<volume>70</volume>: <fpage>40</fpage>&#x02013;<lpage>47</lpage>.
<pub-id pub-id-type="pmid">11907706</pub-id></mixed-citation></ref><ref id="pone.0118084.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Borromeo</surname><given-names>GL</given-names></name>, <name><surname>Tsao</surname><given-names>CE</given-names></name>, <name><surname>Darby</surname><given-names>IB</given-names></name>, <name><surname>Ebeling</surname><given-names>PR</given-names></name> (<year>2011</year>) <article-title>A review of the clinical implications of
bisphosphonates in dentistry</article-title>. <source>Aust Dent J</source>
<volume>56</volume>: <fpage>2</fpage>&#x02013;<lpage>9</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1834-7819.2010.01289.x">10.1111/j.1834-7819.2010.01289.x</ext-link></comment>
<pub-id pub-id-type="pmid">21564110</pub-id></mixed-citation></ref><ref id="pone.0118084.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Zavras</surname><given-names>AI</given-names></name> (<year>2011</year>) <article-title>The impact of bisphosphonates on oral
health: lessons from the past and opportunities for the future</article-title>.
<source>Ann N Y Acad Sci</source>
<volume>1218</volume>: <fpage>55</fpage>&#x02013;<lpage>61</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1749-6632.2010.05876.x">10.1111/j.1749-6632.2010.05876.x</ext-link></comment>
<pub-id pub-id-type="pmid">21291477</pub-id></mixed-citation></ref><ref id="pone.0118084.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Bilezikian</surname><given-names>JP</given-names></name> (<year>2006</year>) <article-title>Osteonecrosis of the jaw&#x02014;Do
biphosphonates pose a risk?</article-title>
<source>New England Journal of Medicine</source>
<volume>355</volume>: <fpage>2278</fpage>&#x02013;<lpage>2281</lpage>.
<pub-id pub-id-type="pmid">17135582</pub-id></mixed-citation></ref><ref id="pone.0118084.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Schwartz</surname><given-names>HC</given-names></name> (<year>1982</year>) <article-title>Osteonecrosis of the jaws: a complication
of cancer chemotherapy</article-title>. <source>Head Neck Surg</source>
<volume>4</volume>: <fpage>251</fpage>&#x02013;<lpage>253</lpage>.
<pub-id pub-id-type="pmid">6896046</pub-id></mixed-citation></ref><ref id="pone.0118084.ref031"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Zervas</surname><given-names>K</given-names></name>, <name><surname>Verrou</surname><given-names>E</given-names></name>, <name><surname>Teleioudis</surname><given-names>Z</given-names></name>, <name><surname>Vahtsevanos</surname><given-names>K</given-names></name>, <name><surname>Banti</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Incidence, risk
factors and management of osteonecrosis of the jaw in patients with multiple
myeloma: a single-centre experience in 303 patients</article-title>. <source>Br J
Haematol</source>
<volume>134</volume>: <fpage>620</fpage>&#x02013;<lpage>623</lpage>.
<pub-id pub-id-type="pmid">16889620</pub-id></mixed-citation></ref><ref id="pone.0118084.ref032"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Badros</surname><given-names>A</given-names></name>, <name><surname>Weikel</surname><given-names>D</given-names></name>, <name><surname>Salama</surname><given-names>A</given-names></name>, <name><surname>Goloubeva</surname><given-names>O</given-names></name>, <name><surname>Schneider</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Osteonecrosis of the
jaw in multiple myeloma patients: clinical features and risk
factors</article-title>. <source>J Clin Oncol</source>
<volume>24</volume>: <fpage>945</fpage>&#x02013;<lpage>952</lpage>.
<pub-id pub-id-type="pmid">16484704</pub-id></mixed-citation></ref><ref id="pone.0118084.ref033"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Bagan</surname><given-names>J</given-names></name>, <name><surname>Scully</surname><given-names>C</given-names></name>, <name><surname>Sabater</surname><given-names>V</given-names></name>, <name><surname>Jimenez</surname><given-names>Y</given-names></name> (<year>2009</year>) <article-title>Osteonecrosis of the jaws in patients
treated with intravenous bisphosphonates (BRONJ): A concise
update</article-title>. <source>Oral Oncol</source>
<volume>45</volume>: <fpage>551</fpage>&#x02013;<lpage>554</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.oraloncology.2009.01.002">10.1016/j.oraloncology.2009.01.002</ext-link></comment>
<pub-id pub-id-type="pmid">19251474</pub-id></mixed-citation></ref><ref id="pone.0118084.ref034"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Dimopoulos</surname><given-names>MA</given-names></name>, <name><surname>Kastritis</surname><given-names>E</given-names></name>, <name><surname>Anagnostopoulos</surname><given-names>A</given-names></name>, <name><surname>Melakopoulos</surname><given-names>I</given-names></name>, <name><surname>Gika</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Osteonecrosis of the
jaw in patients with multiple myeloma treated with bisphosphonates: evidence of
increased risk after treatment with zoledronic acid</article-title>.
<source>Haematologica</source>
<volume>91</volume>: <fpage>968</fpage>&#x02013;<lpage>971</lpage>.
<pub-id pub-id-type="pmid">16757414</pub-id></mixed-citation></ref><ref id="pone.0118084.ref035"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Wessel</surname><given-names>JH</given-names></name>, <name><surname>Dodson</surname><given-names>TB</given-names></name>, <name><surname>Zavras</surname><given-names>AI</given-names></name> (<year>2008</year>) <article-title>Zoledronate, smoking, and obesity are
strong risk factors for osteonecrosis of the jaw: a case-control
study</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>66</volume>: <fpage>625</fpage>&#x02013;<lpage>631</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2007.11.032">10.1016/j.joms.2007.11.032</ext-link></comment>
<pub-id pub-id-type="pmid">18355585</pub-id></mixed-citation></ref><ref id="pone.0118084.ref036"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Marx</surname><given-names>RE</given-names></name>, <name><surname>Sawatari</surname><given-names>Y</given-names></name>, <name><surname>Fortin</surname><given-names>M</given-names></name>, <name><surname>Broumand</surname><given-names>V</given-names></name> (<year>2005</year>) <article-title>Bisphosphonate-induced exposed bone
(osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention,
and treatment</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>63</volume>: <fpage>1567</fpage>&#x02013;<lpage>1575</lpage>.
<pub-id pub-id-type="pmid">16243172</pub-id></mixed-citation></ref><ref id="pone.0118084.ref037"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Mehrotra</surname><given-names>B</given-names></name>, <name><surname>Ruggiero</surname><given-names>S</given-names></name> (<year>2006</year>) <article-title>Bisphosphonate complications including
osteonecrosis of the jaw</article-title>. <source>Hematology Am Soc Hematol Educ
Program</source>: <fpage>356</fpage>&#x02013;<lpage>360</lpage>,
<fpage>515</fpage>
<pub-id pub-id-type="pmid">17124083</pub-id></mixed-citation></ref><ref id="pone.0118084.ref038"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Hoff</surname><given-names>AO</given-names></name>, <name><surname>Toth</surname><given-names>B</given-names></name>, <name><surname>Hu</surname><given-names>M</given-names></name>, <name><surname>Hortobagyi</surname><given-names>GN</given-names></name>, <name><surname>Gagel</surname><given-names>RF</given-names></name> (<year>2011</year>) <article-title>Epidemiology and risk factors for
osteonecrosis of the jaw in cancer patients</article-title>. <source>Ann N Y Acad
Sci</source>
<volume>1218</volume>: <fpage>47</fpage>&#x02013;<lpage>54</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1749-6632.2010.05771.x">10.1111/j.1749-6632.2010.05771.x</ext-link></comment>
<pub-id pub-id-type="pmid">20946574</pub-id></mixed-citation></ref><ref id="pone.0118084.ref039"><label>39</label><mixed-citation publication-type="journal">
<name><surname>De Gobbi</surname><given-names>M</given-names></name>, <name><surname>Viprakasit</surname><given-names>V</given-names></name>, <name><surname>Hughes</surname><given-names>JR</given-names></name>, <name><surname>Fisher</surname><given-names>C</given-names></name>, <name><surname>Buckle</surname><given-names>VJ</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>A regulatory SNP
causes a human genetic disease by creating a new transcriptional
promoter</article-title>. <source>Science</source>
<volume>312</volume>: <fpage>1215</fpage>&#x02013;<lpage>1217</lpage>.
<pub-id pub-id-type="pmid">16728641</pub-id></mixed-citation></ref><ref id="pone.0118084.ref040"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Arduino</surname><given-names>PG</given-names></name>, <name><surname>Menegatti</surname><given-names>E</given-names></name>, <name><surname>Scoletta</surname><given-names>M</given-names></name>, <name><surname>Battaglio</surname><given-names>C</given-names></name>, <name><surname>Mozzati</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Vascular endothelial
growth factor genetic polymorphisms and haplotypes in female patients with
bisphosphonate-related osteonecrosis of the jaws</article-title>. <source>J Oral
Pathol Med</source>
<volume>40</volume>: <fpage>510</fpage>&#x02013;<lpage>515</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1600-0714.2010.01004.x">10.1111/j.1600-0714.2010.01004.x</ext-link></comment>
<pub-id pub-id-type="pmid">21251073</pub-id></mixed-citation></ref><ref id="pone.0118084.ref041"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Ashford</surname><given-names>RU</given-names></name>, <name><surname>Luchetti</surname><given-names>M</given-names></name>, <name><surname>McCloskey</surname><given-names>EV</given-names></name>, <name><surname>Gray</surname><given-names>RL</given-names></name>, <name><surname>Pande</surname><given-names>KC</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Studies of bone
density, quantitative ultrasound, and vertebral fractures in relation to collagen
type I alpha 1 alleles in elderly women</article-title>. <source>Calcif Tissue
Int</source>
<volume>68</volume>: <fpage>348</fpage>&#x02013;<lpage>351</lpage>.
<pub-id pub-id-type="pmid">11685422</pub-id></mixed-citation></ref><ref id="pone.0118084.ref042"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Balla</surname><given-names>B</given-names></name>, <name><surname>Vaszilko</surname><given-names>M</given-names></name>, <name><surname>Kosa</surname><given-names>JP</given-names></name>, <name><surname>Podani</surname><given-names>J</given-names></name>, <name><surname>Takacs</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>New approach to
analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the
jaw</article-title>. <source>Oral Dis</source>
<volume>18</volume>: <fpage>580</fpage>&#x02013;<lpage>585</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1601-0825.2012.01912.x">10.1111/j.1601-0825.2012.01912.x</ext-link></comment>
<pub-id pub-id-type="pmid">22339777</pub-id></mixed-citation></ref><ref id="pone.0118084.ref043"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Basi</surname><given-names>DL</given-names></name>, <name><surname>Hughes</surname><given-names>PJ</given-names></name>, <name><surname>Thumbigere-Math</surname><given-names>V</given-names></name>, <name><surname>Sabino</surname><given-names>M</given-names></name>, <name><surname>Mariash</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Matrix
metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic
acid-treated rats</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>69</volume>: <fpage>2698</fpage>&#x02013;<lpage>2707</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2011.02.065">10.1016/j.joms.2011.02.065</ext-link></comment>
<pub-id pub-id-type="pmid">21752506</pub-id></mixed-citation></ref><ref id="pone.0118084.ref044"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Katz</surname><given-names>J</given-names></name>, <name><surname>Gong</surname><given-names>Y</given-names></name>, <name><surname>Salmasinia</surname><given-names>D</given-names></name>, <name><surname>Hou</surname><given-names>W</given-names></name>, <name><surname>Burkley</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Genetic polymorphisms
and other risk factors associated with bisphosphonate induced osteonecrosis of the
jaw</article-title>. <source>Int J Oral Maxillofac Surg</source>
<volume>40</volume>: <fpage>605</fpage>&#x02013;<lpage>611</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijom.2011.02.002">10.1016/j.ijom.2011.02.002</ext-link></comment>
<pub-id pub-id-type="pmid">21396799</pub-id></mixed-citation></ref><ref id="pone.0118084.ref045"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Massart</surname><given-names>F</given-names></name>, <name><surname>Brandi</surname><given-names>ML</given-names></name> (<year>2009</year>) <article-title>Genetics of the bone response to
bisphosphonate treatments</article-title>. <source>Clin Cases Miner Bone
Metab</source>
<volume>6</volume>: <fpage>50</fpage>&#x02013;<lpage>54</lpage>.
<pub-id pub-id-type="pmid">22461098</pub-id></mixed-citation></ref><ref id="pone.0118084.ref046"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Nuttall</surname><given-names>JM</given-names></name>, <name><surname>Hettema</surname><given-names>EH</given-names></name>, <name><surname>Watts</surname><given-names>DJ</given-names></name> (<year>2012</year>) <article-title>Farnesyl diphosphate synthase, the target
for nitrogen-containing bisphosphonate drugs, is a peroxisomal enzyme in the model
system Dictyostelium discoideum</article-title>. <source>Biochem J</source>
<volume>447</volume>: <fpage>353</fpage>&#x02013;<lpage>361</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BJ20120750">10.1042/BJ20120750</ext-link></comment>
<pub-id pub-id-type="pmid">22849378</pub-id></mixed-citation></ref><ref id="pone.0118084.ref047"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Olmos</surname><given-names>JM</given-names></name>, <name><surname>Zarrabeitia</surname><given-names>MT</given-names></name>, <name><surname>Hernandez</surname><given-names>JL</given-names></name>, <name><surname>Sanudo</surname><given-names>C</given-names></name>, <name><surname>Gonzalez-Macias</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Common allelic
variants of the farnesyl diphosphate synthase gene influence the response of
osteoporotic women to bisphosphonates</article-title>. <source>Pharmacogenomics
J</source>
<volume>12</volume>: <fpage>227</fpage>&#x02013;<lpage>232</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/tpj.2010.88">10.1038/tpj.2010.88</ext-link></comment>
<pub-id pub-id-type="pmid">21151198</pub-id></mixed-citation></ref><ref id="pone.0118084.ref048"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Vairaktaris</surname><given-names>E</given-names></name>, <name><surname>Vassiliou</surname><given-names>S</given-names></name>, <name><surname>Avgoustidis</surname><given-names>D</given-names></name>, <name><surname>Stathopoulos</surname><given-names>P</given-names></name>, <name><surname>Toyoshima</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2009</year>)
<article-title>Bisphosphonate-induced avascular osteonecrosis of the mandible
associated with a common thrombophilic mutation in the prothrombin
gene</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>67</volume>: <fpage>2009</fpage>&#x02013;<lpage>2012</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2009.04.032">10.1016/j.joms.2009.04.032</ext-link></comment>
<pub-id pub-id-type="pmid">19686941</pub-id></mixed-citation></ref><ref id="pone.0118084.ref049"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Zhong</surname><given-names>DN</given-names></name>, <name><surname>Wu</surname><given-names>JZ</given-names></name>, <name><surname>Li</surname><given-names>GJ</given-names></name> (<year>2013</year>) <article-title>Association between CYP2C8 (rs1934951)
polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on
bisphosphonate therapy: a meta-analysis</article-title>. <source>Acta
Haematol</source>
<volume>129</volume>: <fpage>90</fpage>&#x02013;<lpage>95</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000342120">10.1159/000342120</ext-link></comment>
<pub-id pub-id-type="pmid">23171856</pub-id></mixed-citation></ref><ref id="pone.0118084.ref050"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Sarasquete</surname><given-names>ME</given-names></name>, <name><surname>Garcia-Sanz</surname><given-names>R</given-names></name>, <name><surname>Marin</surname><given-names>L</given-names></name>, <name><surname>Alcoceba</surname><given-names>M</given-names></name>, <name><surname>Chillon</surname><given-names>MC</given-names></name>, <etal>et al</etal> (<year>2008</year>)
<article-title>Bisphosphonate-related osteonecrosis of the jaw is associated with
polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide
single nucleotide polymorphism analysis</article-title>. <source>Blood</source>
<volume>112</volume>: <fpage>2709</fpage>&#x02013;<lpage>2712</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2008-04-147884">10.1182/blood-2008-04-147884</ext-link></comment>
<pub-id pub-id-type="pmid">18594024</pub-id></mixed-citation></ref><ref id="pone.0118084.ref051"><label>51</label><mixed-citation publication-type="journal">
<name><surname>English</surname><given-names>BC</given-names></name>, <name><surname>Baum</surname><given-names>CE</given-names></name>, <name><surname>Adelberg</surname><given-names>DE</given-names></name>, <name><surname>Sissung</surname><given-names>TM</given-names></name>, <name><surname>Kluetz</surname><given-names>PG</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>A SNP in CYP2C8 is
not associated with the development of bisphosphonate-related osteonecrosis of the
jaw in men with castrate-resistant prostate cancer</article-title>. <source>Ther
Clin Risk Manag</source>
<volume>6</volume>: <fpage>579</fpage>&#x02013;<lpage>583</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/TCRM.S14303">10.2147/TCRM.S14303</ext-link></comment>
<pub-id pub-id-type="pmid">21151627</pub-id></mixed-citation></ref><ref id="pone.0118084.ref052"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Such</surname><given-names>E</given-names></name>, <name><surname>Cervera</surname><given-names>J</given-names></name>, <name><surname>Terpos</surname><given-names>E</given-names></name>, <name><surname>Bagan</surname><given-names>JV</given-names></name>, <name><surname>Avaria</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>CYP2C8 gene
polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with
multiple myeloma</article-title>. <source>Haematologica</source>
<volume>96</volume>: <fpage>1557</fpage>&#x02013;<lpage>1559</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3324/haematol.2011.042572">10.3324/haematol.2011.042572</ext-link></comment>
<pub-id pub-id-type="pmid">21685474</pub-id></mixed-citation></ref><ref id="pone.0118084.ref053"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>J-Y</given-names></name>, <name><surname>Hwang</surname><given-names>J</given-names></name>, <name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>J-H</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Investigation of
Pathogenic Genes in Peri-Implantitis from Implant Clustering Failure Patients: A
Whole-Exome Sequencing Pilot Study</article-title>. <source>PLoS ONE</source>
<volume>9</volume>: <fpage>e99360</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0099360">10.1371/journal.pone.0099360</ext-link></comment>
<pub-id pub-id-type="pmid">24921256</pub-id></mixed-citation></ref><ref id="pone.0118084.ref054"><label>54</label><mixed-citation publication-type="journal">
<name><surname>Huang da</surname><given-names>W</given-names></name>, <name><surname>Sherman</surname><given-names>BT</given-names></name>, <name><surname>Lempicki</surname><given-names>RA</given-names></name> (<year>2009</year>) <article-title>Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources</article-title>. <source>Nat
Protoc</source>
<volume>4</volume>: <fpage>44</fpage>&#x02013;<lpage>57</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2008.211">10.1038/nprot.2008.211</ext-link></comment>
<pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation></ref><ref id="pone.0118084.ref055"><label>55</label><mixed-citation publication-type="journal">
<name><surname>Kerscher</surname><given-names>O</given-names></name>, <name><surname>Felberbaum</surname><given-names>R</given-names></name>, <name><surname>Hochstrasser</surname><given-names>M</given-names></name> (<year>2006</year>) <article-title>Modification of proteins by ubiquitin and
ubiquitin-like proteins</article-title>. <source>Annu Rev Cell Dev Biol</source>
<volume>22</volume>: <fpage>159</fpage>&#x02013;<lpage>180</lpage>.
<pub-id pub-id-type="pmid">16753028</pub-id></mixed-citation></ref><ref id="pone.0118084.ref056"><label>56</label><mixed-citation publication-type="journal">
<name><surname>Westermann</surname><given-names>S</given-names></name>, <name><surname>Weber</surname><given-names>K</given-names></name> (<year>2003</year>) <article-title>Post-translational modifications regulate
microtubule function</article-title>. <source>Nat Rev Mol Cell Biol</source>
<volume>4</volume>: <fpage>938</fpage>&#x02013;<lpage>948</lpage>.
<pub-id pub-id-type="pmid">14685172</pub-id></mixed-citation></ref><ref id="pone.0118084.ref057"><label>57</label><mixed-citation publication-type="journal">
<name><surname>Griffin</surname><given-names>M</given-names></name>, <name><surname>Casadio</surname><given-names>R</given-names></name>, <name><surname>Bergamini</surname><given-names>CM</given-names></name> (<year>2002</year>) <article-title>Transglutaminases: nature&#x02019;s
biological glues</article-title>. <source>Biochem J</source>
<volume>368</volume>: <fpage>377</fpage>&#x02013;<lpage>396</lpage>.
<pub-id pub-id-type="pmid">12366374</pub-id></mixed-citation></ref><ref id="pone.0118084.ref058"><label>58</label><mixed-citation publication-type="journal">
<name><surname>Rupel</surname><given-names>K</given-names></name>, <name><surname>Ottaviani</surname><given-names>G</given-names></name>, <name><surname>Gobbo</surname><given-names>M</given-names></name>, <name><surname>Contardo</surname><given-names>L</given-names></name>, <name><surname>Tirelli</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>A systematic review
of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw
(BRONJ)</article-title>. <source>Oral Oncol</source>
<volume>50</volume>: <fpage>1049</fpage>&#x02013;<lpage>1057</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.oraloncology.2014.08.016">10.1016/j.oraloncology.2014.08.016</ext-link></comment>
<pub-id pub-id-type="pmid">25240948</pub-id></mixed-citation></ref><ref id="pone.0118084.ref059"><label>59</label><mixed-citation publication-type="journal">
<name><surname>Krishnan</surname><given-names>A</given-names></name>, <name><surname>Arslanoglu</surname><given-names>A</given-names></name>, <name><surname>Yildirm</surname><given-names>N</given-names></name>, <name><surname>Silbergleit</surname><given-names>R</given-names></name>, <name><surname>Aygun</surname><given-names>N</given-names></name> (<year>2009</year>) <article-title>Imaging findings of bisphosphonate-related
osteonecrosis of the jaw with emphasis on early magnetic resonance imaging
findings</article-title>. <source>J Comput Assist Tomogr</source>
<volume>33</volume>: <fpage>298</fpage>&#x02013;<lpage>304</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/RCT.0b013e31817e4986">10.1097/RCT.0b013e31817e4986</ext-link></comment>
<pub-id pub-id-type="pmid">19346864</pub-id></mixed-citation></ref><ref id="pone.0118084.ref060"><label>60</label><mixed-citation publication-type="journal">
<name><surname>Allen</surname><given-names>MR</given-names></name>, <name><surname>Burr</surname><given-names>DB</given-names></name> (<year>2009</year>) <article-title>The pathogenesis of bisphosphonate-related
osteonecrosis of the jaw: so many hypotheses, so few data</article-title>.
<source>J Oral Maxillofac Surg</source>
<volume>67</volume>: <fpage>61</fpage>&#x02013;<lpage>70</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2009.01.007">10.1016/j.joms.2009.01.007</ext-link></comment>
<pub-id pub-id-type="pmid">19371816</pub-id></mixed-citation></ref><ref id="pone.0118084.ref061"><label>61</label><mixed-citation publication-type="journal">
<name><surname>Zafar</surname><given-names>S</given-names></name>, <name><surname>Coates</surname><given-names>DE</given-names></name>, <name><surname>Cullinan</surname><given-names>MP</given-names></name>, <name><surname>Drummond</surname><given-names>BK</given-names></name>, <name><surname>Milne</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Zoledronic acid and
geranylgeraniol regulate cellular behaviour and angiogenic gene expression in
human gingival fibroblasts</article-title>. <source>Journal of Oral Pathology
&#x00026; Medicine: n/a-n/a</source>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/jop.12135">10.1111/jop.12135</ext-link></comment>
<pub-id pub-id-type="pmid">24261541</pub-id></mixed-citation></ref><ref id="pone.0118084.ref062"><label>62</label><mixed-citation publication-type="journal">
<name><surname>Luckman</surname><given-names>SP</given-names></name>, <name><surname>Hughes</surname><given-names>DE</given-names></name>, <name><surname>Coxon</surname><given-names>FP</given-names></name>, <name><surname>Graham</surname><given-names>R</given-names></name>, <name><surname>Russell</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Nitrogen-containing
bisphosphonates inhibit the mevalonate pathway and prevent post-translational
prenylation of GTP-binding proteins, including Ras</article-title>. <source>J Bone
Miner Res</source>
<volume>13</volume>: <fpage>581</fpage>&#x02013;<lpage>589</lpage>.
<pub-id pub-id-type="pmid">9556058</pub-id></mixed-citation></ref><ref id="pone.0118084.ref063"><label>63</label><mixed-citation publication-type="journal">
<name><surname>Kwon</surname><given-names>YD</given-names></name>, <name><surname>Kim</surname><given-names>DY</given-names></name>, <name><surname>Ohe</surname><given-names>JY</given-names></name>, <name><surname>Yoo</surname><given-names>JY</given-names></name>, <name><surname>Walter</surname><given-names>C</given-names></name> (<year>2009</year>) <article-title>Correlation between serum C-terminal
cross-linking telopeptide of type I collagen and staging of oral
bisphosphonate-related osteonecrosis of the jaws</article-title>. <source>J Oral
Maxillofac Surg</source>
<volume>67</volume>: <fpage>2644</fpage>&#x02013;<lpage>2648</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2009.04.067">10.1016/j.joms.2009.04.067</ext-link></comment>
<pub-id pub-id-type="pmid">19925985</pub-id></mixed-citation></ref><ref id="pone.0118084.ref064"><label>64</label><mixed-citation publication-type="journal">
<name><surname>O&#x02019;Ryan</surname><given-names>FS</given-names></name>, <name><surname>Khoury</surname><given-names>S</given-names></name>, <name><surname>Liao</surname><given-names>W</given-names></name>, <name><surname>Han</surname><given-names>MM</given-names></name>, <name><surname>Hui</surname><given-names>RL</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Intravenous
bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early
indicator</article-title>. <source>J Oral Maxillofac Surg</source>
<volume>67</volume>: <fpage>1363</fpage>&#x02013;<lpage>1372</lpage>. <comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joms.2009.03.005">10.1016/j.joms.2009.03.005</ext-link></comment>
<pub-id pub-id-type="pmid">19531404</pub-id></mixed-citation></ref></ref-list></back></article>